Sector intelligence and perspective
April 23, 2018
Investors are frazzled by the sector’s downside trends
With a byproduct of negativity; as usual after damning sessions, the oversold will hear the sirens song with a shift to the upside
To then be lured back to the bottom with even further damage to their pricing
It’s just another tempest as quarterly financial results i.e. earnings beginning 5/1
Out and about: The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (ATHX) plan to conduct a P2 clinical trial evaluating Athersys’ MultiStem® cell therapy for early treatment and prevention of complications after severe traumatic injury - BUY
Pre-open indications: One (1) BUY
Where the understanding of the indications sheds light on share pricing!
April 9, 2018
In a cash deal 72% above 30-day average, AVXS had closed at $115.91 down -$3.69 or -3.09%
This is NVS' second notable gene therapy deal this year after it agreed to pay $105 million upfront and up to another $65 million in milestone payments for rights to Spark Therapeutics’ (ONCE) blindness treatment Luxturna outside the US.
AVXS-101 is a treatment for spinal muscular atrophy (SMA)
The transaction is seen closing in mid-2018.
April 23, 2018
The downside funnels the sector even lower
With 16 sessions of April’s closings (of 40 covered companies) having nine (9) negative, six (6) positive and one (1) neutral closes; today is the fourth (4th ) losing streak in a row
The NASDAQ tanked (-0.25%) along with the IBB (-0.16%) and the Russell 2000 (RUT-0.13%)
Pre-open indication: 1 HIT
Research note: 1 HIT
As I had stated, “Speculation will be a thematic as those equities without news will hem and haw.”
End of day briefing; the “numbers” speak!
April 23, 2018
PSTI closed Friday at $1.20 (-$0.04) and is UP +$0.04 in the pre-market The 5-year joint project was granted $2.5 million from the U.S. NIH
April 16, 2018
Closed down -$0.04 and is up +$0.0 or +7.28% to $1.09 ONVO continues to map out a range of relevant conditions for creating NASH, including all components of the disease (fat accumulation, inflammation and fibrosis).
April 12, 2018
ONVO closed down -$0.01 to $1.01 and is UP +$0.04 or +$0.04 or +3.96 These new data points provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
